Defensive Perimeter in the Central Nervous System: Predominance of Astrocytes and Astrogliosis during Recovery from Varicella-Zoster Virus Encephalitis

John E. Carpenter, Amy C. Clayton, Kevin C. Halling, Daniel J. Bonthius, Erin M. Buckingham, Wallen Jackson, Steven M. Dotzler, J. Patrick Card, Lynn W. Enquist, Charles Grose

Varicella-zoster virus (VZV) is a highly neurotropic virus that can cause infections in both the peripheral nervous system and the central nervous system. Several studies of VZV reactivation in the peripheral nervous system (herpes zoster) have been published, while exceedingly few investigations have been carried out in a human brain. Notably, there is no animal model for VZV infection of the central nervous system. In this report, we characterized the cellular environment in the temporal lobe of a human subject who recovered from focal VZV encephalitis. The approach included not only VZV DNA/RNA analyses but also a delineation of infected cell types (neurons, microglia, oligodendrocytes, and astrocytes). The average VZV genome copy number per cell was 5. Several VZV regulatory and structural gene transcripts and products were detected. When colocalization studies were performed to determine which cell types harbored the viral proteins, the majority of infected cells were astrocytes, including aggregates of astrocytes. Evidence of syncytium formation within the aggregates included the continuity of cytoplasmic positive for the VZV glycoprotein H (gH) fusion-complex protein within a cellular profile with as many as 80 distinct nuclei. As with other causes of brain injury, these results suggested that astrocytes likely formed a defensive perimeter around foci of VZV infection (astrogliosis). Because of the rarity of brain samples from living humans with VZV encephalitis, we compared our VZV results with those found in a rat encephalitis model following infection with the closely related pseudorabies virus and observed similar perimeters of gliosis.

**ABSTRACT**

Varicella-zoster virus (VZV) is a highly neurotropic virus that can cause infections in both the peripheral nervous system and the central nervous system. Several studies of VZV reactivation in the peripheral nervous system (herpes zoster) have been published, while exceedingly few investigations have been carried out in a human brain. Notably, there is no animal model for VZV infection of the central nervous system. In this report, we characterized the cellular environment in the temporal lobe of a human subject who recovered from focal VZV encephalitis. The approach included not only VZV DNA/RNA analyses but also a delineation of infected cell types (neurons, microglia, oligodendrocytes, and astrocytes). The average VZV genome copy number per cell was 5. Several VZV regulatory and structural gene transcripts and products were detected. When colocalization studies were performed to determine which cell types harbored the viral proteins, the majority of infected cells were astrocytes, including aggregates of astrocytes. Evidence of syncytium formation within the aggregates included the continuity of cytoplasmic positive for the VZV glycoprotein H (gH) fusion-complex protein within a cellular profile with as many as 80 distinct nuclei. As with other causes of brain injury, these results suggested that astrocytes likely formed a defensive perimeter around foci of VZV infection (astrogliosis). Because of the rarity of brain samples from living humans with VZV encephalitis, we compared our VZV results with those found in a rat encephalitis model following infection with the closely related pseudorabies virus and observed similar perimeters of gliosis.

**IMPORTANCE**

Investigations of VZV-infected human brain from living immunocompetent human subjects are exceedingly rare. Therefore, much of our knowledge of VZV neuropathogenesis is gained from studies of VZV-infected brains obtained at autopsy from immunocompromised patients. These are not optimal samples with which to investigate a response by a human host to VZV infection. In this report, we examined both flash-frozen and paraffin-embedded formalin-fixed brain tissue of an otherwise healthy young male with focal VZV encephalitis, most likely acquired from VZV reactivation in the trigeminal ganglion. Of note, the cellular response to VZV infection mimicked the response to other causes of trauma to the brain, namely, an ingress of astrocytes and astrogliosis around an infectious focus. Many of the astrocytes themselves were infected; astrocytes aggregated in clusters. We postulate that astrogliosis represents a successful defense mechanism by an immunocompetent human host to eliminate VZV reactivation within neurons.

Varicella-zoster virus (VZV) is an alphaherpesvirus that can cause infections in both the peripheral nervous system (PNS) and the central nervous system (CNS). The neurotropism of VZV is manifested most commonly in the PNS as herpes zoster (shingles) (1). Herpes zoster is the reactivation of the same virus that entered a latent state decades earlier during primary VZV infection. The most common sites of VZV latency are the dorsal root ganglia and the trigeminal ganglia (2). Herpes zoster has been investigated in both human samples and in the severe combined immunodeficient mouse/dorsal root ganglion model (3–5).

Upon reactivation from the trigeminal ganglion, herpes zoster ophthalmicus is the prototypical expression of trigeminal zoster. In addition to innervation of the skin of the upper face, sensory afferent fibers originating in the V1 and V2 branches of trigeminal ganglion travel into the meninges of the frontal and temporal lobes, respectively (6, 7). Furthermore, VZV reactivation within the trigeminal ganglion does not necessarily lead to virus exit within the same fibers it entered following primary infection. As a result, VZV can travel in afferent fibers from the trigeminal ganglion to the cerebrum, where it can cause CNS disease in the absence of a clinically apparent zoster exanthem.
In contrast to peripheral herpes zoster, samples of brain tissue from a human who recovers from a VZV infection of the CNS are exceedingly rare. We previously published a brief case report of focal VZV encephalitis (8). The lesion (~1 cm in diameter) was located mainly in the gray matter of the temporal lobe. The infection likely arose in the pia arachnoid overlying the gray matter, innervated by terminal fibers of the meningeal nerve emanating from the V1 branch of the trigeminal ganglion. Because a low-grade glioma was the initial diagnosis, the entire lesion was removed neurosurgically. When a pathology examination failed to confirm the diagnosis of tumor, a preliminary investigation of possible viral pathogens detected VZV antigens and wild-type VZV DNA in the brain tissues.

Following an extensive literature search regarding alphaherpesvirus encephalitis, it was apparent that almost no neuropathology data were available about the cellular response to VZV encephalitis in a human subject who overcame his infection, as opposed to VZV-infected brain samples collected postmortem (9–11). Postmortem brain samples may not provide insight into cells required for recovery from VZV infection; in fact, postmortem samples from immunocompromised subjects likely represent a failure of an as yet poorly characterized response to contain or eliminate a herpesvirus infection. Our subsequent more detailed investigation of the VZV-infected brain tissue found an unexpected predominance of infected astrocytes and astrogliaosis. Because there is no animal model for VZV encephalitis by which to compare our findings in this human brain sample, we reexamined older reports of CNS infection with the closely related pseudorabies virus (PRV) (12). Our subsequent PRV studies confirmed a strikingly similar cellular response found in one model of experimental PRV encephalitis.

MATERIALS AND METHODS
Reagents for identification of VZV proteins and cell types in brain. The anti-VZV reagents included the following monoclonal antibodies (MAbs): 3B3 (anti-glycoprotein E [anti-gE]), 233 (anti-gC), 206 (anti-gH), and human anti-gH. All murine MAbs have been characterized (13–15); likewise, the human anti-gH MAb has been described (16). All MAb reagents have been shown not to react nonspecifically with human tissue; since the human subject was not of blood group A, there was no concern about nonviral reactivity of antibody to A antigen in brain cells (8, 17). The anticeull reagents included a rabbit antineurofilament antibody against neurons (Sigma N4142), mouse anti-GFAP MAb (Sigma G3893), and cyanine 3(Cy3)-conjugated mouse anti-gial fibrillary acidic protein (anti-GFAP) MAb (Sigma C9205) against astrocytes, mouse antibody against oligodendrocytes (RIP, NIH Developmental Studies Hybridoma Bank), and a red fluorescent Griffonia (Bandeiraea) simplicifolia plant lectin I, isolectin B4 (Invitrogen 121412), against microglia. For the reagents not conjugated with a fluoroprobe, we purchased the following secondary reagents: Alexa 488, 546, and 633 fluoroprobes conjugated to goat anti-rabbit IgG, goat anti-mouse IgG, or goat anti-human IgG (Invitrogen).

Protocols for confocal microscopy and Imaris software. The brain biopsy specimen had been flash-frozen at −70°C. For confocal microscopy, several 10-μm frozen sections were cut in a cryostat and adhered to glass slides. The sections were incubated with antibody probes by the described methods and then viewed with a Zeiss LSM710 spectral confocal microscope, using 10 ×, 20 ×, 40 ×, and 63 × high-numerical-aperture oil immersion objective lenses (15, 18). Image size was set to either 512 by 512 or 1,024 by 1,024 pixels. Emission detection bandwidths were configured by Zeiss Zen control software. The confocal pinhole was set to 1 Airy unit. The z-stack acquisition intervals were selected to satisfy Nyquist sampling criteria. To further assess colocalization of labeled proteins in individual labeled brain cells, three-dimensional (3D) animations were produced from z-stacks comprising up to 40 images, with the aid of Imaris software (Imaris version 7.6 reference manual; Bitplane).

Protocol for TEM of human tissue. For electron microscopy, the frozen brain sample was thawed to approximately −10°C, and then a small piece (2 by 2 by 2 mm) was excised. That piece was further subdivided and the sections placed in BEEM capsules containing 2% glutaraldehyde in phosphate-buffered saline (PBS) at 4°C. The samples were then prepared for transmission electron microscopy (TEM) using previously described methodology (19). Briefly, the sample was further fixed in 1% OsO4 plus 1.5% KFe(CN)6 in PBS for 2 h; washed twice with water, and then further stained with 2% uranyl acetate in water for 30 min. The tissue was then dehydrated in a graded series of ethanol solutions: 25%, 50%, and 75% for 15 min each followed by 100% ethanol twice for 30 min each, 50% ethanol–Epon (Eponate 12) for 2 h, 100% Epon for 2 h, and 100% Epon for 18 h. The tissue was then polymerized at 100°C for 18 h. Microtomy yielded thin sections of the embedded brain tissue that were then placed on TEM grids, further stained with 4% uranyl acetate in water and then 1% lead citrate with water, washing after each stain. The grids were then air dried and imaged using a JEOL 1230 transmission electron microscope fitted with a Gatan camera.

Protocol for rat pseudorabies microscopy study. Two adult male Sprague-Dawley rats weighing approximately 300 g were used in the investigation. The animals were acclimated to the animal housing unit in a biosafety level 2 (BSL-2) laboratory for 2 days prior to the onset of the experiment. The temperature (22 to 25°C) and light-dark cycle (12 h of light, with light on at 0700) were standardized in the colony room, and food and water were available ad libitum. On the day of the experiment, the animals were anesthetized with isoflurane, and their heads were secured in a stereotaxic frame. Following shaving of the head and sterilization of the scalp with Betadine, an incision was made to expose the dorsal surface of the skull. A beveled 1-μl Hamilton syringe loading with PRV strain RV-152 was lowered into the interpositus nucleus through a craniotomy drilled at coordinates obtained from the rat brain atlas of Swanson (20). Virus was injected into the interpositus nucleus at 10 nl/min for a final volume of 100 nl using a nanoliter pump (model 310; Stoelting). Ten minutes following completion of the injection, the needle was removed from the brain, the craniotomy was filled with bone wax, the scalp was closed with wound clips, and the animal was placed under a heat lamp to recover consciousness. When fully ambulatory, it was returned to its home cage. At 48 h following virus infection, each animal was deeply anesthetized with 390 mg/ml sodium pentobarbital (Fatal Plus; Vortech Pharmaceuticals) and perfused transcardially with buffered aldehyde solutions containing 5% glutaraldehyde and 4% paraformaldehyde in 0.1 M sodium cacodylate buffer. The brain was removed, postfixed in the same fixative overnight at 4°C, and sectioned serially at 100 μm/section through the rostrocaudal extent of the inferior olive. Sections were postfixed for 1 h at room temperature in 1% osmium tetroxide and 1.5% potassium ferricyanide in the cacodylate buffer. The sections were washed in multiple changes of buffer, dehydrated in a graded series of ethanol, passed through three changes of acetone, and then infiltrated and flat embedded with Epon–Aradite plastic resin, according to previously published procedures (21). Alternating series of thick and ultrathin sections were cut using a Leica Ultracut E ultramicrotome. Thick sections were stained with toluidine blue. Ultrathin sections were collected on Formvar–coated slot grids, stained with uranyl acetate and lead citrate, and examined and photographed using a Morgani transmission electron microscope.

(See this study was submitted to the Institutional Review Board at the University of Iowa, who deemed the human research exempt. All experimental procedures involving rats were conducted in accordance with the National Research Council’s Guide for the Care and Use of Laboratory Animals (48) and were approved by the University of Pittsburgh Institutional Animal Care and Use Committee.)
RESULTS

VZV transcriptome within the focal encephalitis. In an earlier report, we had only amplified one VZV gene (ORF62) from brain tissue (8). To better assess the status of the viral genome within the CNS, we performed more complete DNA and RNA analyses. To this end, we extracted DNA and mRNA from sub-sections of the frozen tissue. We measured copies of both cellular and viral DNA using primers to VZV open reading frame 62 (ORF62) and ORF68 and the cellular gene coding for GAPDH. Using a standard curve, the number of genome copies was calculated from the PCR measurements in panel A. Given a known number of cells in the positive control, we computed the number of VZV genome copies per cell. Based on similar GAPDH amplifications in the positive control and the brain tissue in Fig. 1A, we reasoned that the brain tissue contained a similar number of cells to the diluted positive control. Thus, we predicted 3 to 7 copies per cell, compared to the positive control with 11,000 copies per cell. To test the latter possibility that DNA replication was restricted in the human brain, we carried out quantitative PCR (qPCR) measurements against cDNA from VZV-infected MRC-5 fibroblast cells (positive control) versus cDNA from the brain tissue using the primers listed in Table 1 to a subset of VZV glycoprotein and regulatory transcripts (Fig. 1C and D). The GAPDH threshold cycle (C<sub>T</sub>) was 8 cycles later for the brain tissue than the positive control, indicating 2<sup>8</sup> fewer cells. Assuming there are 1 million cells in the positive control, then the small piece of brain tissue consisted of approximately 4,000 cells. In general,
the level of VZV transcripts in the brain tissue was consistently less than that of the positive control by 24 to 26, a result suggesting that a productive infection was occurring in far fewer than 10% of the cells within the brain tissue.

**Survey of infected cells within focal VZV encephalitis.** After collecting the genomic data, we postulated that neurons would be the cell in which infection would be most easily detected. Therefore, we selected an established antibody probe for neurons and two anti-VZV monoclonal antibody probes. Based on the fact that VZV gE (ORF68) is an abundant gene product during VZV infection, we chose a well-characterized anti-gE MAb, 3B3, with high-affinity binding for a linear epitope that is known not to cross-react with uninfected brain tissue (22, 23). When we examined sections that were dually labeled for VZV gE and neuronal filaments by confocal microscopy, we observed scattered foci of VZV gE reactivity, but virtually no VZV gE immunolabeling was found in neurons (Fig. 2A). We expanded this observation by obtaining a z-stack of images through the focus of gE immunolabel and staining cells with the cell wall of microglia. As seen in Fig. 2B, gE immunolabel was detected but did not colocalize with individual microglial cells when a z-stack was examined. Thereafter, we investigated whether VZV infection was found in a third cell type, namely, oligodendrocytes. Because the anti-oligodendrocyte antibody was murine, we selected a human anti-gH (ORF37) monoclonal antibody as the VZV probe to facilitate labeling with two fluoroprobes of different wavelengths. This experiment produced a pivotal result—namely, VZV antigen was detected in stellate cells that did not coimmunolabel with the oligodendrocyte antibody (Fig. 2C). The absence of any RIP-positive cells indicated that this brain section was taken from gray matter. Because of the distinctive stellate morphology of the infected cells, we postulated that VZV infection may be more easily detectable in astrocytes.

**Infected astrocytes within focal VZV encephalitis.** Immuno-detection of glial fibrillary acidic protein (GFAP) is the standard method for identifying intermediate filaments in activated astro-

| VZV gene | Primer sequence |
|----------|----------------|
| ORF4     | 5'-CTC GTA CTC TCC CCG AAC TG-3' |
| ORF10    | 5'-ATT TTC CGG TGG TGT GGA-3' |
| ORF14    | 5'-GGA ACT CGA CGG ACC TAT CA-3' |
| ORF21    | 5'-GTT GGA CCC GAC TGG AT-3' |
| ORF29    | 5'-TCT TGT GAA CCA AGC CAT GA-3' |
| ORF31    | 5'-CGT GGG ATT ATT GGT TTT GG-3' |
| ORF37    | 5'-GCT CAT TCT TCC AGC TGT CC-3' |
| ORF60    | 5'-TCG GGA ATC GTG GTT AAG AC-3' |
| ORF66    | 5'-CAA ACC TGG ACC TGG AAA GA-3' |
| ORF62    | 5'-CCT TGG AAA CCA CAT GAT CGT-3' |
| ORF63    | 5'-TGA AGA CGA TAG CGA CGA TG-3' |
| ORF66    | 5'-GCC ACC TCC CCA TAT GTG AC-3' |
| ORF67    | 5'-TCC AGG TTA CCC GAA AAG AC-3' |
| ORF68    | 5'-CCC GTG AAA CCC CGG AAC GT-3' |

In order to investigate whether virus was present in microglia, we performed a similar confocal microscopy experiment after labeling cells with the *Griffonia* plant isolecitin B4, which adheres to the cell wall of microglia. As seen in Fig. 2B, gE immunolabel was again detected but did not colocalize with individual microglial cells when a z-stack was examined. Therefore, we investigated whether VZV infection was found in a third cell type, namely, oligodendrocytes. Because the anti-oligodendrocyte antibody was murine, we selected a human anti-gH (ORF37) monoclonal antibody as the VZV probe to facilitate labeling with two fluoroprobes of different wavelengths. This experiment produced a pivotal result—namely, VZV antigen was detected in stellate cells that did not coimmunolabel with the oligodendrocyte antibody (Fig. 2C). The absence of any RIP-positive cells indicated that this brain section was taken from gray matter. Because of the distinctive stellate morphology of the infected cells, we postulated that VZV infection may be more easily detectable in astrocytes.
FIG 3 Colocalization of VZV glycoproteins with astrocytes. Twelve images from two z-series are shown. (A to F) Brain section from the first brain section labeled with Hoechst H33342 (blue in panels A1 to E1), human anti-VZV gH MAb (green in panels A2 to E2), and murine anti-GFAP antibody (red in panels A3 to E3). The merge of panels F1 to -4 is shown in panel F1, with a scale bar to outline the astrocyte. (G to M) Brain section from second brain section labeled with Hoechst H33342 (blue in panels G1, H1, K1, L1, and M1), human anti-VZV gH MAb (green in panels G2, H2, K2, L2, and M2), and murine anti-GFAP antibody (red in panels G3, H3, K3, L3, and M3). The merge of panels J1 to -4 is shown in panel J1, with a scale bar to outline the astrocyte. Colocalization was seen (arrows).
Because the anti-astrocyte antibodies were of murine origin, we continued to use the human anti-gH MAb as the VZV probe for this set of experiments. As noted in Materials and Methods, we selected two anti-GFAP reagents, one of which was conjugated with a Cy3 fluoroprobe. During these confocal microscopy experiments, it became readily apparent that there was considerable colocalization of the VZV antigen within cells immunolabeled with GFAP reagent. Two representative z-stacks are shown in Fig. 3. Furthermore, several of the immunopositive cells were large. After further examination, we concluded that some large GFAP-positive VZV-infected cells were clustered into aggregates. Since gH is one component of the VZV fusion complex, we reasoned that gH would clearly define syncytia.

To further assess the aggregates of infected cells, z-stacks containing 40 slices were converted by Imaris software into 3D animations; the 3D images confirmed that extensive VZV gH-positive antigen was found within GFAP-positive cells. A 2D frame from one of the animations shows a syncytium of astrocytes con-
taining about 80 nuclei (Fig. 4). Because of the importance of this set of immunolabeling experiments, over 200 confocal micrographs were examined. During the same investigations, we failed to find evidence of VZV gH reactivity within either circular structures (2D images) or cylindrical structures (3D animations) that could represent blood vessels.

**Further analysis of aggregates.** In order to further clarify the relationship of GPAP immunolabeling to these aggregates, we probed a larger section of the flash-frozen brain tissue with antibodies to VZV gH and the astrocytic marker GFAP and visualized at low magnification (Fig. 5). A wide-area montage revealed a moderate number of dense gH-positive cellular aggregates that were scattered across the brain section (Fig. 5A). Closer examination of two gH-positive areas (Fig. 5B and C) displayed a downregulation of GFAP immunolabel within the aggregates, while neighboring astrocytes showed signs of early infection and upregulation of GFAP. These results strongly supported previous observations that VZV infection of astrocytes caused a downregulation of GFAP expression (27).

**Detection of the VZV true late gC protein in gH-positive cells.** To determine whether VZV can complete its replication cycle in astrocytes, we next investigated whether the true late (gamma-2) gC protein (ORF14) was detectable (15). As a positive control for infected astrocytes (Fig. 3), we again selected the anti-gH antibody of human origin. As can be seen in Fig. 6, VZV gC was detected within infected cells, but the relative amount of gC immunolabeling was considerably less than with gH immunolabeling. The limited gC production combined with near-normal gC transcription results (Fig. 1) suggested a delayed expression of the gamma-2 viral products in astrocytes, similar to that seen previously in cultured neurons (28, 29).

**Cytoarchitecture of the VZV-infected human brain.** To gain further insight into the role and extent of reactive gliosis in VZV-induced neuropathology, we examined a portion of the excised temporal lobe tissue using transmission electron microscopy (TEM). Observers at both the University of Iowa and the University of Pittsburgh independently examined ultrathin sections of the tissue and identified the cell types (30). Systematic scanning of numerous sections revealed focal aggregations of degenerating neurons within the tissue. In every case, one or more astrocytes surrounded the degenerating neurons, entirely isolating them from the adjacent brain parenchyma (Fig. 7A, B, and D). Tight junctions enhanced the integrity of this barrier by binding the complex interlacing network of astrocytic processes surrounding each neuron. A remarkable uniformity in morphology characterized each of these glial barriers. Particularly notable in this regard was accumulation of electron-dense proteinaceous material at the outermost border of the barrier, giving the appearance of a basal lamina surrounding the cell (Fig. 7A, B, and D to F). However, careful analysis at high magnification demonstrated that the proteinaceous material was within the limiting membrane of the astrocyte, forming a continuous band adjacent to the plasmalemma of the outermost processes. High-magnification analysis also demonstrated that the dense material was continuous into branches of the outer process that invaded deeper layers and fused with processes exhibiting a more lucent cytoplasm. The fusion of processes within this complicated interweaving network presented clear evidence of syncytium formation that was consistent with confocal microscopic observations (Fig. 4). Evidence of syncytium formation was also commonly observed by the continuity of cytoplasm between profiles with separate nuclei (inset in Fig. 7A).

Examination of the interface between degenerating neurons...
FIG 7 Reactive astrocytes and astrogliosis in VZV-infected human brain. The relationships of reactive astroglia (ast) to degenerating neurons (n) are illustrated in the electron micrographs. Barrier astrocytes formed intimate relations with degenerating neurons, entirely isolating the degenerating neurons from the surrounding neuropil (A to D). In some cases, more than one reactive astrocyte contributed to this barrier (A), with the cells fusing to form a syncytium (inset in panel A). These astrocytes were also the source of thin interleaving processes that isolated synaptic profiles within the neuropil (C; arrow in panel E). Reactive
and the barrier astrocytes revealed clear evidence of phagocytic activity (Fig. 7G). Astrocyte processes routinely invaded the soma of degenerating neurons, and phagosomes were prevalent throughout the astrocyte cytoplasm. Thus, it was evident that the barrier astrocytes not only isolated degenerating neurons from the brain parenchyma but also were involved in actively removing them through phagocytosis. Systematic analysis of numerous reactive astrocytes revealed a paucity of viral particles. Occasional evidence of capsid formation was observed in the nuclei of the barrier astrocytes intimately associated with degenerating neurons. However, enveloped virions were underrepresented within the cytoplasm of these cells. Reactive astroglia in the surrounding brain parenchyma rarely exhibited evidence of viral replication.

**Cytoarchitecture of rodent brain infected with pseudorabies virus.** Because the reactive astroglia observed in the samples of VZV-infected human brain tissue exhibited features similar to those previously documented in the rat CNS following PRV infection (31), we conducted a new comparative analysis of this response in rats infected with PRV strain RV-152 (Fig. 8). This PRV recombinant of the Bartha strain is transported retrogradely through neural circuits and produces cytopathology at advanced stages of viral replication. In this experiment, the virus was injected into cerebellar neurons that receive projections from neurons in the inferior olive (Fig. 8A and B). The glial response to viral replication was then characterized 48 h later. Examination of toluidine blue-stained thick sections revealed aggregations of intensely basophilic glial cells adjacent to infected neurons (Fig. 8C). Electron microscopic examination of adjacent ultrathin sections demonstrated that these multicellular aggregates were intimately associated with infected neurons, often investing the neuron with a dense array of cells and processes (Fig. 8D to G). Analysis of these glial aggregates revealed that they contained a dense concentration of astrocytes and microglia, consistent with earlier reports of the nonneuronal response to PRV infection (31, 32). The reactive astroglia displayed morphological features similar to those observed in the VZV-infected human brain tissue. These shared features included the formation of complex interleaving process networks (Fig. 9A), evidence of syncytium formation (Fig. 9B and C), intimate associations of astrocytes with somata of infected neurons (Fig. 9D and E), and the presence of phagosomes within the cellular cytoplasm (Fig. 9A and C). A subset of reactive astrocytes also contained capsids within the nucleus and cytoplasm (Fig. 9A to F), but enveloped pseudorabies virions at the plasma membrane were difficult to find.

**DISCUSSION**

A central finding of this report is that astrocytes are an important component of the CNS response to VZV neurotropism in humans who recover from their infection. The role of astrocytes during the CNS stress response is a subject of increasing investigation (33, 34). Astrocytes outnumber neurons in the human brain. While there are an estimated 16 billion neurons in the cerebral cortex, the number of astrocytes is presumably higher (35). Astrocytes in humans are larger and more complex that those in most primates and all other mammals. Furthermore, the 3D territory over which a human astrocyte extends is much greater than that seen in all nonhuman astrocytes. For example, the processes extending from a single human cortical astrocyte are estimated to encompass a domain including hundreds, perhaps thousands, of neuronal synapses (36).

Astrocytes in the human cortex are classified into 4 subgroups: (i) interlaminar, (ii) protoplasmic, (iii) varicose projection, and (iv) fibrous (37). The first three are located entirely or in part within the gray matter, while the fibrous astrocytes are found mainly in white matter. The extended family includes Muller glia in the retina and Bergmann glia in the cerebellum. Astrocytes are essential polyvalent cells in the brain. They are no longer considered just the glue (“glia” is derived from the Latin word for glue) or the matrix that holds the rest of the brain together (38). Instead, they participate in several functions, including energy metabolism, ion exchange, and glutamate homeostasis, as well as acting as sentinels for viral infection via their expression of the Toll-like receptor 3 (TLR3) (39, 40). Furthermore, astrocytes are involved in cross talk with both neurons and microglia; fiber-like processes of astrocytes are in contact with both synapses and blood vessels. Through these shared connections, astrocytic end feet titrate blood flow in response to various levels of synaptic activity.

Gliosis is the term that describes a proliferation of glial cells in the CNS as a response to injury (34). Gliosis has not been recognized widely as a consequence of VZV infection in the CNS, although gliosis was observed by standard hematoxylin and eosin (H&E) visualization in this brain tissue (8). As noted in the initial report, the pathology was mainly concentrated in the gray matter of the temporal lobe. Furthermore, our data convincingly demonstrated that the predominant infected cell was the astrocyte. Based on their size and morphology, we postulate that they were mostly protoplasmic astrocytes. These are the most numerous of the 4 subclasses, and they are located in this region of the temporal lobe. Their diameters range from <100 to >400 μm, with an average around 150 μm. Aggregates of fused astrocytes that immunolabeled with the VZV fusion complex anti-gH antibody were also observed.

There is also a question of whether astrocytes were infected primarily or only secondarily after infection of a neuron. Obviously we did not have an earlier brain biopsy specimen to examine. Furthermore, there is no good animal model for VZV enceph-
FIG 8 Experimental paradigm and cellular response to PRV infection in rat brain. (A and B) Paradigm. Injection of the PRV Bartha strain into the interpositus nucleus of the rat cerebellum (A) resulted in retrograde spread of virus to infect neurons within the inferior olive (B). The brown reaction product visible in panel B represents immunocytochemical localization of viral antigens marking infected cells within the inferior olive and surrounding brain stem 2 days after injection of virus. (C) Thick section. The panel is a toluidine blue-stained 1-μm section from the boxed area shown in panel B. Intensely basophilic cells define reactive glia in relation to infected neurons. (D to G) Thin sections. Processing of tissue adjacent to the thick section for TEM analysis revealed infected neurons (n) and reactive astrogliosis (ast) within the cerebellum. Because the number of astrocytes was so large, some are labeled internally with an asterisk. Several infected neurons exhibited vacuolization and were intimately associated with reactive glial cells and their processes. Marker bars for panels D to G are 6 μm.
Astrogliosis in the PRV-infected rat brain. The interrelations of multicellular aggregates of reactive astroglia adjacent to infected neurons from the fields shown in Fig. 8 are illustrated at higher magnification. Infected neurons exhibited pathological vacuolization (D and E) and contained mature virions (arrows). Aggregates of reactive glia in the immediate vicinity were directly apposed to infected neurons (D and E). Astroglia in aggregates also gave rise to interdigitating processes that isolated infected neurons from brain parenchyma and often contained capsids with no sign of envelopment (inset in panel A). Cells that contained larger number of capsids in either the nucleus (F) or cytoplasm (boxed portions are of panel A shown at higher magnification in panel B) typically exhibited cytoplasm that was more electron dense and also commonly displayed evidence of syncytium formation (B). Phagosomes (p) provided evidence of phagocytic activity by reactive astroglia within each aggregate, and astrocytes within the aggregate also completely invested adjacent capillaries (cap in panel C). Marker bars by panel: A, B, D, E, and F and inset in E, 1 μm; inset in A, 200 nm; C, 2 μm.
VZV vasculopathy as a cause of the CNS neuropathology (44, 45).

fibers travel along the carotid arteries within the white matter and with larger blood vessels. A greater number of trigeminal afferent fibers lie in the outer gray matter of the lateral temporal lobe, not a region but more slowly than in human fibroblasts (27, 43). The latter replication proceeded more quickly in astrocytes than in neurons.

However, there was little or no spread of infection beyond the astrocytes that were initially infected (32). For this current project, a second independent investigation of a PRV-infected brain was carried out. Astrocytes were easily identified around necrotic neurons; thus, the second study confirmed and expanded the observations about astrocytes seen in the original study. Taken together, our results with VZV infection of astrocytes in the human brain appear very similar to PRV infection within astrocytes in the rat brain.

With regard to VZV infection in the brain, another question is why the antiviral property of astrocytes was not previously recognized. One explanation is that VZV meningoencephalitis and vasculopathy can occur in the absence of skin rash and would be difficult to diagnose (11). A second explanation is that nearly all prior VZV investigations in the brain were performed on specimens collected at autopsy at various times after death. We postulate that humans with fatal VZV CNS infections likely represent situations in which (i) the human host was immunocompromised and (ii) the astrocytic defensive wall failed. As an example, there was a case report of fatal CNS disease due to disseminated VZV infection in an AIDS patient before current effective therapeutic protocols (42). The authors recognized that astrocytes were infected as part of the pathological process in the brain, but they did not postulate a defensive role. The same group subsequently studied VZV replication in astrocyte cell lines and showed the VZV replication proceeded more quickly in astrocytes than in neurons but more slowly than in human fibroblasts (27, 43). The latter situations suggest that cross talk between astrocytes and neurons is required for astrocytes to form a defensive perimeter in the infected human brain. In a similar manner to protection afforded by astroglial scar following other traumatic brain events, therefore, astrogliosis appears to be a hallmark of a successful innate and adaptive immune response after VZV reactivation and transit into the brain (33, 34).

Finally, the case in this report does not represent an example of VZV vasculopathy as a cause of the CNS neuropathology (44, 45). However, we suggest that the underlying neuropathogenesis is related. Namely, by chance, this human brain sample was infected by VZV exiting a branch of the trigeminal nerve that innervates the outer gray matter of the lateral temporal lobe, not a region with larger blood vessels. A greater number of trigeminal afferent fibers travel along the carotid arteries within the white matter and therefore can convey reactive virus from the ganglion to the adventitia of arteries, eventually leading to inflammation and stroke (46, 47).

ACKNOWLEDGMENTS

This research project was supported in part by NIH grant AI89716 and NIH grant P40 RR018604.

FUNDING INFORMATION

HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) provided funding to Charles Grose under grant number AI89716. HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) provided funding to J. Patrick Card under grant number P40 RR018604.

REFERENCES

1. Weller TH. 1983. Varicella and herpes zoster. Changing concepts of the natural history, control, and importance of a not-so-benign virus. N Engl J Med 309:1434–1440.
2. Hope-Simpson RE. 1965. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 58:9–20.
3. Zerbini L, Senn N, Oliver SL, Arvin AM. 2014. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 12:197–210. http://dx.doi.org/10.1038/nrmicro3215.
4. Kennedy PG, Rovnak J, Badani H, Cohrs RJ. 2015. A comparison of HSV-1 and VZV latency and reactivation. J Gen Virol 96:1581–1602. http://dx.doi.org/10.1099/vir.0.000128.
5. Arvin AM. 2006. Investigations of the pathogenesis of varicella zoster virus infection in the SCID-hu mouse model. Herpes 13:75–80.
6. O’Connor TP, van der Kooy D. 1986. Pattern of intracranial and extracranial projections of trigeminal ganglion cells. J Neurosci 6:2200–2207.
7. Liu-Chen LY, Han DH, Moskowitz MA. 1983. Pia arachnoid contains substance P originating from trigeminal neurons. Neuroscience 9:803–808. http://dx.doi.org/10.1016/0306-4522(83)90268-3.
8. Halling G, Giannini C, Britton JW, Lee RW, Watson RE, Jr, Terrell CL, Parney IF, Buckingham EM, Carpenter JE, Grose C. 2014. Focal encephalitis following varicella-zoster virus reactivation without rash in a healthy immunized young adult. J Infect Dis 210:713–716. http://dx.doi.org/10.1093/infdis/jiu137.
9. Whiteley RJ, Gnann JW. 2002. Viral encephalitis: familiar infections and emerging pathogens. Lancet 359:507–513. http://dx.doi.org/10.1016/S0140-6736(02)07681-X.
10. Smith G. 2012. Herpesvirus transport to the nervous system and back again. Annu Rev Microbiol 66:153–176. http://dx.doi.org/10.1146/annurev-micro-092611-150051.
11. Gilden D. 2013. Neuroinfections. Oxford Press, Oxford, United Kingdom.
12. Pomeranz LE, Reynolds AE, Hengartner CJ. 2005. Molecular biology of pseudorabies virus: impact on neurovirology and veterinary medicine. Microbiol Mol Biol Rev 69:462–500. http://dx.doi.org/10.1128/MMBR.69.3.462-500.2005.
13. Grose C, Edwards DP, Friedrichs WE, Weigle KA, McGuire WL. 1983. Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun 40:381–388.
14. Santos RA, Hatfield CC, Cole NL, Padilla JA, Moffat JF, Arvin AM, Ruyechan WT, Hay J, Grose C. 2000. Varicella-zoster virus e85 escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology 275:306–317. http://dx.doi.org/10.1006/viro.2000.5057.
15. Storlie J, Carpenter JE, Jackson W, Grose C. 2008. Discordant varicella-zoster virus glycoprotein C expression and localization between cultured cells and human skin vesicles. Virology 382:171–181. http://dx.doi.org/10.1016/j.virol.2008.09.031.
16. Akahori Y, Suzuki K, Daido K, Iwai M, Yoshida Y, Asano Y, Kurosawa Y, Shiraki K. 2009. Characterization of neutralizing epitopes of varicella-zoster virus glycoprotein H J Virol 83:2020–2024. http://dx.doi.org/10.1128/JVI.02097-08.
17. Zerbini I, Sobel RA, Lai M, Trigida R, Steain M, Abendroth A, Arvin A. 2012. Apparent expression of varicella-zoster virus proteins in latency resulting from reactivity of murine and rabbit antibodies with human blood group A determinants in sensory neurons. J Virol 86:578–583. http://dx.doi.org/10.1128/JVI.05950-11.
18. Jackson W, Yamada M, Moninger T, Grose C. 2013. Visualization and quantitation of abundant macropathology in virus-infected cells by confocal three-dimensional fluorescence imaging. J Virol Methods 193:244–250. http://dx.doi.org/10.1016/j.jviromet.2013.06.018.

Downloaded from http://jvi.asm.org on July 15, 2018 by guest
response to CNS damage and disease. Neuron 81:229–248. http://dx.doi.org/10.1016/j.neuron.2013.12.034.

35. Herculano-Houzel S, Manger PR, Kaas JH. 2014. Brain scaling in mammalian evolution as a consequence of concerted and mosaic changes in numbers of neurons and average neuronal cell size. Front Neuronatq 8:77. http://dx.doi.org/10.3389/fnana.2014.00077.

36. Oberheim NA, Takano T, Han X, He W, Lin JH, Wang F, Xu Q, Wyatt JD, Pilcher W, Ojemann JG, Ransom BR, Goldman SA, Nedergaard M. 2009. Uniquely hominid features of adult human astrocytes. J Neurosci 29:3276–3287. http://dx.doi.org/10.1523/JNEUROSCI.4707-08.2009.

37. Oberheim NA, Goldman SA, Nedergaard M. 2012. Heterogeneity of astrocytic form and function. Methods Mol Biol 814:23–43. http://dx.doi.org/10.1007/82_2009_4.

38. Volterra A, Meldolesi J. 2005. Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 6:626–640. http://dx.doi.org/10.1038/nrn1722.

39. Farina C, Krumholz M, Giese T, Hartmann G, Aloisi F, Meinel I. 2005. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 159:12–19. http://dx.doi.org/10.1016/j.jneuroim.2004.09.009.

40. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP. 2005. TLR signaling tails innate immune responses in human microglia and astrocytes. J Immunol 175:4320–4330. http://dx.doi.org/10.4049/jimmunol.175.7.4320.

41. Chou J, Kern ER, Whitey RJ, Roizman B. 1990. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250:1262–1266. http://dx.doi.org/10.1126/science.2173860.

42. Ryder JW, Croen K, Kleinschmidt-DeMasters BK, Ostrove JM, Straus SE, Cohn DL. 1986. Progressive encephalitis three months after resolution of cutaneous zoster in a patient with AIDS. Ann Neurol 19:182–188. http://dx.doi.org/10.1002/ana.410190212.

43. Assouline C, Levin MJ, Major EO, Forghani B, Straus SE, Ostrove JM. 1990. Varicella-zoster virus infection of human astrocytes, Schwann cells, and neurons. Virology 179:834–844. http://dx.doi.org/10.1016/0042-6822(90)90152-H.

44. Gilden DH, Kleinschmidt-DeMasters BK, Wellish M, Hedley-Whyte ET, Rentier B, Mahalingam R. 1996. Varicella zoster virus, a cause of waning and waning vasculitis: the New England Journal of Medicine case 5-1995 revisited. Neurology 47:1441–1446. http://dx.doi.org/10.1212/WNL.47.6.1441.

45. Nagel MA, Gilden D. 2014. Update on varicella zoster virus vasculopathy. Curr Infect Dis Rep 16:407. http://dx.doi.org/10.1007/s11908-014-0407-z.

46. Nagel MA, Traktinskiy I, Azarkh Y, Kleinschmidt-DeMasters B, Hedley-Whyte T, Russman A, VanEgmond EM, Stenmark K, Frid M, Mahalingam R, Wellish M, Choe A, Cordery-Cotter R, Crohs RJ, Gilden D. 2011. Varicella zoster virus vasculopathy: analysis of virus-infected arteries. Neurology 77:364–370. http://dx.doi.org/10.1212/WNL.0b013e3182267bfa.

47. Grose C, Adams HP. 2014. Reassessing the link between herpes zoster ophthalmicus and stroke. Expert Rev Anti Infect Ther 12:527–530. http://dx.doi.org/10.1586/14787210.2014.904203.

48. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.